众生药业：控股子公司签署RAY1225注射液项目许可协议，获得首付款及里程碑付款总金额为人民币10亿元

Core Viewpoint - The announcement highlights a licensing agreement between the company's subsidiary, Zhongsheng Ruichuang, and Qilu Pharmaceutical for the production and commercialization of RAY1225 injection in China [1] Group 1: Financial Terms - Zhongsheng Ruichuang will receive a total of RMB 1 billion in upfront and milestone payments, which includes an upfront payment of RMB 200 million and up to RMB 800 million in development and sales milestone payments [1] - After the product is launched, Zhongsheng Ruichuang is entitled to receive a double-digit percentage of the net sales of the licensed product [1] Group 2: Approval and Transaction Details - The transaction has been approved by the board of directors and does not require submission for shareholder approval, indicating it is not classified as a related party transaction or a major asset restructuring [1]